featured
Intensified- vs Standard-Dose Infliximab Induction Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Gastroenterology & Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol 2024 Nov 01;9(11)981-996, MC Choy, CFD Li Wai Suen, D Con, K Boyd, R Pena, K Burrell, O Rosella, D Proud, R Brouwer, A Gorelik, D Liew, WR Connell, EK Wright, KM Taylor, A Pudipeddi, M Sawers, B Christensen, W Ng, J Begun, G Radford-Smith, M Garg, N Martin, DR van Langenberg, NS Ding, L Beswick, RW Leong, MP Sparrow, P De CruzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.